Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland

Original article
Bonani M, Balaphas A, Bedino G, Bühler L, Dutkowski P, Fausch K, Gluderer S, Graf N, Hirt-Minkowski P, Müllhaupt B, Schönholzer C, Schulz MM, Venzin R, Wüthrich RP
Swiss Med Wkly. 2021;151:w20453

Non-adherence to immunosuppressive therapy in patients following solid organ transplantation is associated with an increased risk of transplant rejection and graft loss. A high pill burden can adversely affect patients’ implementation of their treatment regimens and may lead to omitting doses of medication. The aim of this study was to investigate medication implementation adherence in liver and kidney transplant recipients converted from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus.

Laparoscopic liver resection: a single-centre experience

Original article
Ghielmetti M, Ramser M, Oertli D
Swiss Med Wkly. 2021;151:w20391

In the last two decades laparoscopic liver resection has developed dramatically. This study aimed to describe the experience and the results of laparoscopic liver resection at a single centre over 12 years.

Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland

Original article
Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N
Swiss Med Wkly. 2021;151:w20399

In the era of pangenotypic treatment regimens against hepatitis C virus infection, data from postmarketing observational studies are crucial to better understand the treatment patterns used in specific countries and treatment outcomes under real-life conditions.

Systematic review of pneumothoraces after endoscopic retrograde cholangiopancreatography

Systematic review
Lehmann V, Keller W, Egger B
Swiss Med Wkly. 2020;150:w20199

Pneumothoraces after endoscopic retrograde cholangiopancreatography (ERCP) are an uncommon but potentially lethal complication. Little evidence is available on their epidemiology, diagnosis and therapy.

Nonalcoholic fatty liver disease burden – Switzerland 2018–2030

Original article
Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, Moriggia A, Muellhaupt B, Negro F, Razavi H, Semela D, Estes C
Swiss Med Wkly. 2019;149:w20152

As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland.

Position statement on the use of biosimilars in inflammatory bowel disease

Review article: Biomedical intelligence
Burri E, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S
Swiss Med Wkly. 2019;149:w20148

A biosimilar is a biological medicine highly similar to another, already approved medicine. Physicians should be aware of definition, approval process, and biochemical and clinical features that distinguish biosimilars from the reference product.

Non-invasive diagnosis of liver steatosis: ready for primetime?

Viewpoint
Goossens N
Swiss Med Wkly. 2019;149:w20108

The formal diagnosis of hepatic steatosis relies on liver histology based on a liver biopsy, which is an invasive procedure that is not required in the majority of cases. Due to the high prevalence of liver steatosis, in particular in the context of an increase in NAFLD incidence, there has been renewed interest in use of non-invasive tools to assess the presence of liver disease.

Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre

Original article
Sawatzki M, Meyenberger C, Brand S, Semela D
Swiss Med Wkly. 2019;149:w20087

Focal liver lesions (FLLs) are common on conventional ultrasound. Contrast-enhanced ultrasound (CEUS) is highly accurate for differentiating benign and malignant FLLs, with an accuracy comparable to that of contrast-enhanced CT and MRI.

Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience

Original article
Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D
Swiss Med Wkly. 2019;149:w20077

Accurate diagnosis and staging of non-alcoholic fatty liver disease are essential for its management. Controlled attenuation parameter is a new noninvasive measurement made during transient elastography to assess liver steatosis.

Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions

Original article
Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Müllhaupt B, Negro F, Semela D
Swiss Med Wkly. 2019;149:w14694

The Swiss Hepatitis Strategy aims to eliminate hepatitis C virus infection and associated liver-related morbidity and mortality by 2030. To date, Little has been done to identify the epidemiology of HCV on the regional, or micro, level.

Verpassen Sie keinen Artikel!

close